egfr/erbb1

EBE-A22 (PD153035 Analog 63) is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.

Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.

Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).

JNJ28871063 hydrochloride is an orally active, ATP-competitive, and highly selective pan-ErbB kinase inhibitor with IC50 values of 22 nM for ErbB1, 38 nM for ErbB2, and 21 nM for ErbB4, JNJ28871063 hydrochloride effectively inhibits phosphorylation of key tyrosine residues in EGFR and ErbB2, crossing the blood–brain barrier, and demonstrating antitumor efficacy in xenograft models overexpressing EGFR and ErbB2.

ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.

Anti-ERBB1/EGFR/HER1 Antibody is a human-derived antibody expressed in CHO cells, targeting ERBB1/EGFR/HER1. It possesses a human IgG1 heavy chain and a human κ light chain, with an estimated molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.